Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies
Be The Match BioTherapies and Cryoport have joined forces in a strategic partnership that aims to revolutionize the cell therapy market. This collaboration will enhance the capabilities of IntegriCell™, a standardized bioprocessing, cryopreservation, and distribution solution for the global cell therapy industry.
IntegriCell™, with its cryopreservation facilities in the United States and Europe, is well-positioned to support both decentralized and centralized manufacturing models. This will ultimately accelerate patient access to innovative cell and gene therapies. By combining Be The Match BioTherapies’ expertise in donor identification and collection of high-quality starting material with Cryoport’s cryopreservation, bioprocessing, and global logistics capabilities, the integrated solution will provide global bioprocessing and cryopreservation support throughout the United States and Europe.
The IntegriCell™ solution is designed to deliver optimized cellular starting material by utilizing standardized bioprocessing and cryopreservation protocols performed by experienced teams. The goal is to provide cell and gene therapy researchers, developers, and manufacturers with consistent starting materials that are cryopreserved to improve manufacturing slot utilization, leading to increased yields. This will enable new cell and gene therapies to reach the market faster and more affordably.
Mark Sawicki, President and CEO at Cryoport Systems Inc., expressed excitement about the collaboration, stating, “Cell and gene therapy developers have struggled to deliver consistent starting materials with the cell yields that meet their stringent standards — until now. Be The Match BioTherapies is a world-class partner dedicated to advancing the cell and gene therapy ecosystem, and this collaboration presents a major opportunity to work together to deliver best-in-class solutions to the cell and gene therapy industry.”
Chris McClain, Senior Vice President Sales and Business Development at Be The Match BioTherapies, echoed this sentiment, saying, “We are excited to work with Cryoport to continue to set new standards, expand accessibility, and accelerate progress in the development of potentially life-saving cell and gene therapies. We believe IntegriCell represents a vital leap forward in the cell therapy ecosystem, one that will ultimately lead to more consistent manufacturing yields and better clinical outcomes.”
Be The Match BioTherapies is a leading cell and gene therapy solutions provider, offering customizable services to support the end-to-end cell therapy supply chain. With the backing of the National Marrow Donor Program®/Be The Match® and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization is dedicated to accelerating patient access to life-saving cell and gene therapies.
Cryoport, Inc., on the other hand, is a global provider of innovative products and services to the fast-growing Cell & Gene Therapy industry. With strategic locations across 17 countries, Cryoport’s global platform offers mission-critical bio-logistics, bio-storage, bio-processing, cryopreservation, and cryogenic systems to the life sciences markets worldwide.
This partnership between Be The Match BioTherapies and Cryoport represents a significant step forward in advancing the field of cell and gene therapies. By combining their respective expertise, they are poised to make a lasting impact on the industry, ultimately improving patient outcomes and transforming the future of medicine.